Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Jin Zhang et al.|The Lancet|2019Cited by 3.3k
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung CancerÓscar Arrieta, Rafael Rosell, Feliciano Barrón et al.|JAMA Oncology|2020Cited by 153
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, María José Serrano, Andrés F. Cardona et al.|Critical Reviews in Oncology/Hematology|2020Cited by 135
Human recombinant activated protein C for severe sepsisArturo J Martí-Carvajal, Andrés F. Cardona, Georgia Salanti|Cochrane Database of Systematic Reviews|2008Cited by 36
Human recombinant activated protein C for severe sepsisArturo J Martí-Carvajal, Andrés F. Cardona, Georgia Salanti|Cochrane Database of Systematic Reviews|2007Cited by 33